PlasmaGen Biosciences, a biopharmaceutical company focused on plasma-derived therapeutics, has raised ₹150 crore in a minority equity financing round at a valuation exceeding ₹1,500 crore. The round was led by ViNS Bioproducts, with participation from HNI family offices, pharmaceutical entrepreneurs and existing investors.
Company Background
Founded in 2010 and headquartered in Bengaluru, PlasmaGen operates in the specialised segment of blood plasma-derived medicines. The company has raised more than ₹600 crore in funding to date and is positioning itself as a differentiated plasma biopharmaceutical platform from India.
Use of Capital
PlasmaGen said the fresh capital will be deployed to scale its international operations, expand its product portfolio and strengthen organisational and leadership capabilities. The funding is expected to support the company’s transition from domestic scale-up to global market entry.
Operational Momentum
The company commenced commercial operations at its high-tech plasma fractionation facility in 2024. PlasmaGen said the facility is only the fifth plasma fractionation unit in India, underscoring its capital-intensive manufacturing base. Since becoming operational, the company has reported rapid revenue growth and is preparing to enter international markets.
Investor Perspective
According to the company, the financing reflects investor confidence in PlasmaGen’s operating model, manufacturing infrastructure and long-term potential. Investors are backing the company’s ability to build a sustainable and scalable plasma biopharmaceutical platform addressing unmet medical needs.
Global Expansion Plans
PlasmaGen has identified distribution partners in key export markets and is advancing regulatory approvals to commence international operations. Domestically, it continues to strengthen its market presence through a portfolio of plasma-derived therapies.
Leadership Strengthening
To support its next phase of growth, PlasmaGen has strengthened its leadership team with the appointment of Vivek V Kamath as chief executive officer, Sethu Madhavan as chief operating officer for manufacturing and technical operations, and Arnav Jain as chief financial officer.
Keep building. Keep learning. Keep growing with StartupByDoc.